A model to predict the 6-Minute Walk Distance in Pompe disease
Open Access
- 22 April 2025
- journal article
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 12 (4) , 487-496
Abstract
Background: Pompe disease is a rare neuromuscular disorder caused by acid alpha-glucosidase deficiency, leading to glycogen accumulation and progressive striated muscle weakness. The 6-minute walk test (6MWT) is commonly used to assess functional capacity in neuromuscular diseases but can be challenging for severely affected ambulant patients. Objective: This study aimed to develop and validate predictive models for 6MWT performance using simpler, less demanding tests. Methods: This retrospective monocentric study included 74 patients with Pompe disease (712 visits) and a mean follow-up of 6.6 ± 3.8 years. Functional assessments included the 6MWT, 10-meter walk test (10mWT) which was specifically used to determine gait speed, timed tests, strength and respiratory measures, and the Motor Function Measure (MFM-32). Linear regression models were developed to predict 6MWT speed, with validation using an 80%-20% training-testing split. Results: The cohort had an equal male-to-female ratio, with a mean age of 54.4 ± 13.5 years. The 10mWT speed showed a strong correlation with 6MWT speed (R = 0.91, p < 0.0001), confirming its potential as a surrogate measure. The most practical predictive model included 10mWT speed, age, sex, height, and weight, achieving an adjusted R 2 of 0.86. This model balances simplicity and accuracy, relying on easily measurable parameters suitable for routine clinical use. More complex models, including variables such as the MFM-32 or supine-to-sit time, offered only marginal improvements in accuracy. Conclusion: The 10mWT offers a robust and less exhausting alternative to the 6MWT for assessing walking capacity in Pompe disease, particularly for ambulant patients with severe mobility limitations. Its strong correlation with the 6MWT and ease of implementation support its integration into clinical practice and trials.Keywords
This publication has 26 references indexed in Scilit:
- Pompe Disease: a Clinical, Diagnostic, and Therapeutic OverviewCurrent Treatment Options in Neurology, 2022
- Long‐term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe RegistryJournal of Inherited Metabolic Disease, 2020
- Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?European Journal of Paediatric Neurology, 2019
- Are the average gait speeds during the 10 meter and 6 minute walk tests redundant in Parkinson disease?Gait & Posture, 2017
- Population-based reference values for the 1-min sit-to-stand testInternational Journal of Public Health, 2013
- Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfaMolecular Genetics and Metabolism, 2012
- Relations Between 6 Minute Walking Distance and 10 Meter Walking Speed in Patients With Multiple Sclerosis and StrokeArchives of Physical Medicine and Rehabilitation, 2012
- Pompe's diseaseThe Lancet, 2008
- A motor function measure scale for neuromuscular diseases. Construction and validation studyNeuromuscular Disorders, 2005
- Cardiorespiratory fitness and walking ability in subacute stroke patients11No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the author(s) or upon any organization with which the author(s) is/are associated.Archives of Physical Medicine and Rehabilitation, 2003